Peroxidase activation of 4-hydroxytamoxifen to free radicals detected by epr spectroscopy

被引:15
作者
Davies, AM
Malone, ME
Martin, EA
Jones, RM
Jukes, R
Lim, CK
Smith, LL
White, INH
机构
[1] MRC,TOXICOL UNIT,LEICESTER LE1 9HN,LEICS,ENGLAND
[2] DEPT CHEM,LEICESTER LE1 9HN,LEICS,ENGLAND
关键词
peroxidase; 4-hydroxytamoxifen; 4-hydroxytoremifene; tamoxifen; free radical; glutathione; DNA damage;
D O I
10.1016/S0891-5849(96)00345-0
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
4-Hydroxytamoxifen is a major metabolite of the antiestrogenic drug tamoxifen used in the treatment of women with breast cancer. 4-Hydroxytamoxifen is broken down by a horseradish peroxidase/H2O2 system very much more rapidly than tamoxifen and causes much greater DNA damage determined by P-32-postlabelling. EPR spin trapping of 4-hydroxytamoxifen reaction products in the presence of the free radical trap 5,5-dimethyl-1-pyrroline N-oxide, together with glutathione as a hydrogen donor, resulted in the generation of a species with the characteristics of the glutathione thiyl radical (a(N) similar to 15.3 G, a(H) similar to 16.2 G). Support for the creation of thiyl radicals comes from the close to stoichiometric time dependent formation of glutathione disulfide concomitant with the loss of glutathione. Similar results were obtained using 4-hydroxytoremifene but no radical formation or glutathione loss could be detected using 3-hydroxytamoxifen (droloxifene). On-line LC-ESI MS analysis of the incubation products from 4-hydroxytamoxifen has identified three products with a protonated molecular mass of 773, consistent with the formation of dimers of 4-hydroxytamoxifen. The role that radical mechanisms have in the carcinogenic effects of tamoxifen in the endometrium or other target organs of women taking this drug remains to be established. Copyright (C) 1996 Elsevier Science Inc.
引用
收藏
页码:423 / 431
页数:9
相关论文
共 32 条
[1]   DNA-DAMAGE AS ASSESSED BY P-32 POSTLABELING IN 3 RAT STRAINS EXPOSED TO DIETARY TAMOXIFEN - THE RELATIONSHIP BETWEEN CELL-PROLIFERATION AND LIVER-TUMOR FORMATION [J].
CARTHEW, P ;
RICH, KJ ;
MARTIN, EA ;
DEMATTEIS, F ;
LIM, CK ;
MANSON, MM ;
FESTING, MFW ;
WHITE, INH ;
SMITH, LL .
CARCINOGENESIS, 1995, 16 (06) :1299-1304
[2]  
DAHME E, 1994, ONKOLOGIE, V17, P67
[3]   PEROXIDASE ACTIVATION OF TAMOXIFEN AND TOREMIFENE RESULTING IN DNA-DAMAGE AND COVALENTLY BOUND PROTEIN ADDUCTS [J].
DAVIES, AM ;
MARTIN, EA ;
JONES, RM ;
LIM, CK ;
SMITH, LL ;
WHITE, INH .
CARCINOGENESIS, 1995, 16 (03) :539-545
[4]   ENDOMETRIAL CANCER IN TAMOXIFEN-TREATED BREAST-CANCER PATIENTS - FINDINGS FROM THE NATIONAL SURGICAL ADJUVANT BREAST AND BOWEL PROJECT (NSABP) B-14 [J].
FISHER, B ;
COSTANTINO, JP ;
REDMOND, CK ;
FISHER, ER ;
WICKERHAM, DL ;
CRONIN, WM ;
BOWMAN, D ;
COUTURE, J ;
DIMITROV, NV ;
EVANS, J ;
FARRAR, W ;
KAVANAH, M ;
LICKLEY, HL ;
MARGOLESE, R ;
PATERSON, AHG ;
ROBIDOUX, A ;
SHIBATA, H ;
TERZ, J .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (07) :527-537
[5]  
GREAVES P, 1993, CANCER RES, V53, P3919
[6]  
HARD GC, 1993, CANCER RES, V53, P4534
[7]   PEROXIDASE-ACTIVITY IN GLANDS AND STROMA OF HUMAN-ENDOMETRIUM [J].
HOLINKA, CF ;
GURPIDE, E .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1980, 138 (06) :599-603
[8]  
JONES RM, 1995, J CHROMATOGR A, V722, P249
[9]   TAMOXIFEN AND TUMORIGENICITY - A PREDICTABLE CONCERN [J].
JORDAN, VC .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (09) :623-626
[10]  
LIEN EA, 1989, CANCER RES, V49, P2175